Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival

被引：11
|
作者：
Tettero, Jesse M. [1 ,2 ]
Ngai, Lok Lam [1 ,2 ]
Bachas, Costa [1 ,2 ]
Breems, Dimitri A. [3 ]
Fischer, Thomas [4 ]
Gjertsen, Bjorn T. [5 ]
Gradowska, Patrycja [6 ]
Griskevicius, Laimonas [7 ,8 ]
Janssen, Jeroen J. W. M. [1 ,2 ]
Juliusson, Gunnar [9 ]
Maertens, Johan [10 ]
Manz, Markus G. [11 ]
Pabst, Thomas [12 ,13 ,14 ]
Passweg, Jakob [12 ,14 ]
Porkka, Kimmo [15 ]
Valk, Peter J. M. [16 ,17 ]
Loewenberg, Bob [16 ,17 ]
Ossenkoppele, Gert J. [1 ,2 ]
Cloos, Jacqueline [1 ,2 ]
机构：
[1] Univ Amsterdam, Locat VUmc, Med Ctr, Amsterdam, Netherlands
[2] Canc Ctr Amsterdam, Imaging & Biomarkers, Amsterdam, Netherlands
[3] Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium
[4] Otto von Guericke Univ Hosp Magdeburg, Magdeburg, Germany
[5] Haukeland Hosp, Bergen, Norway
[6] Erasmus MC Canc Inst, Data Ctr, Dutch Belgian Hemato Oncol Cooperat Grp, Rotterdam, Netherlands
[7] Vilnius Univ Hosp, Santaros Klin, Vilnius, Lithuania
[8] Vilnius Univ, Vilnius, Lithuania
[9] Skanes Univ Hosp, Lund, Sweden
[10] Univ Hosp Gasthuisberg, Leuven, Belgium
[11] Univ Hosp, Zurich, Switzerland
[12] Swiss Grp Clin Canc Res SAKK, Bern, Switzerland
[13] Inselspital Bern, Dept Med Oncol, Bern, Switzerland
[14] Univ Hosp, Basel, Switzerland
[15] Helsinki Univ Hosp, Canc Ctr, Helsinki, Finland
[16] Erasmus Univ, Med Ctr MC, Rotterdam, Netherlands
[17] Erasmus MC Canc Inst, Rotterdam, Netherlands
来源：
HAEMATOLOGICA | 2023年 / 108卷 / 10期
关键词：
ADULTS; AML; YOUNGER;
D O I：
10.3324/haematol.2022.282639
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2794 / 2798
页数：5
相关论文
共 50 条
  • [41] A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia
    Torrebadell, Montserrat
    Diaz-Beya, Marina
    Kalko, Susana G.
    Pratcorona, Marta
    Nomdedeu, Josep
    Navarro, Alfons
    Gel, Bernat
    Brunet, Salut
    Sierra, Jorge
    Camos, Mireia
    Esteve, Jordi
    LEUKEMIA & LYMPHOMA, 2018, 59 (10) : 2394 - 2404
  • [42] Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)
    Maffini, Enrico
    Labopin, Myriam
    Beelen, Dietrich Wilhelm
    Kroeger, Nicolaus
    Arat, Mutlu
    Wilson, Keith M. O.
    Bay, Jacques-Olivier
    Ganser, Arnold
    Martin, Hans
    Passweg, Jakob
    Kottaridis, Panagiotis D.
    Yakoub-Agha, Ibrahim
    Porras, Rocio Parody
    Wagner, Eva Maria
    Esteve, Jordi
    Lanza, Francesco
    Nagler, Arnon
    Mohty, Mohamad
    BONE MARROW TRANSPLANTATION, 2022, 57 (10) : 1556 - 1563
  • [43] Integration of measurable residual disease by WT1 gene expression and flow cytometry identifies pediatric patients with high risk of relapse in acute myeloid leukemia
    Ahmed, Sonia
    Elsherif, Mariam
    Yassin, Dina
    Elsharkawy, Nahla
    Mohamed, Ayman S.
    Yasser, Nouran
    Elnashar, Amr
    Hafez, Hanafy
    Kolb, Edward A.
    Elhaddad, Alaa
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [44] Comparable Outcomes After Alternative and Matched Sibling Donor Hematopoietic Stem Cell Transplantation and the Role of Molecular Measurable Residual Disease for Acute Myeloid Leukemia in Elderly Patients
    Cho, Byung-Sik
    Yahng, Seung-Ah
    Min, Gi-June
    Park, Silvia
    Park, Sung-Soo
    Shin, Seung-Hwan
    Jeon, Young-Woo
    Yoon, Jae-Ho
    Lee, Sung-Eun
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Lee, Seok
    Min, Chang-Ki
    Cho, Seok-Goo
    Kim, Dong-Wook
    Lee, Jong Wook
    Kim, Myungshin
    Kim, Yonggoo
    Kim, Hee-Je
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (09): : 774.e1 - 774.e12
  • [45] Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study
    Rodriguez-Arboli, Eduardo
    Martinez-Cuadron, David
    Rodriguez-Veiga, Rebeca
    Carrillo-Cruz, Estrella
    Gil-Cortes, Cristina
    Serrano-Lopez, Josefina
    Bernal del Castillo, Teresa
    del Pilar Martinez-Sanchez, Maria
    Rodriguez-Medina, Carlos
    Vidriales, Belen
    Miguel Bergua, Juan
    Benavente, Celina
    Garcia-Boyero, Raimundo
    Herrera-Puente, Pilar
    Algarra, Lorenzo
    Sayas-Lloris, Maria Jose
    Fernandez, Rosa
    Labrador, Jorge
    Lavilla-Rubira, Esperanza
    Barrios-Garcia, Manuel
    Tormo, Mar
    Serrano-Maestro, Alfons
    Lucia Sossa-Melo, Claudia
    Garcia-Belmonte, Daniel
    Vives, Susana
    Ignacio Rodriguez-Gutierrez, Juan
    Albo-Lopez, Carmen
    Paz Garrastazul-Sanchez, Maria
    Colorado-Araujo, Mercedes
    Mariz, Jose
    Sanz, Miguel Angel
    Antonio Perez-Simon, Jose
    Montesinos, Pau
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (04): : 311.e1 - 311.e10
  • [46] History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission
    Rashidi, Armin
    Linden, Michael A.
    DeFor, Todd E.
    Warlick, Erica
    Bejanyan, Nelli
    Yohe, Sophia
    Weisdorf, Daniel J.
    Ustun, Celalettin
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (10) : 1032 - 1036
  • [47] Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group
    Benetton, Maddalena
    Merli, Pietro
    Walter, Christiane
    Hansen, Maria
    Da Ros, Ambra
    Polato, Katia
    Tregnago, Claudia
    Abrahamsson, Jonas
    Strocchio, Luisa
    Sonneveld, Edwin
    Fogelstrand, Linda
    Von Neuhoff, Nils
    Reinhardt, Dirk
    Hasle, Henrik
    Pigazzi, Martina
    Locatelli, Franco
    BIOMEDICINES, 2022, 10 (07)
  • [48] Application of prophylactic or pre-emptive therapy after allogeneic transplantation for high-risk patients with t(8;21) acute myeloid leukemia
    Guo, Wenwen
    Liu, Xin
    Wang, Mingyang
    Liu, Jia
    Cao, Yigeng
    Zheng, Yawei
    Zhai, Weihua
    Chen, Xin
    Zhang, Rongli
    Ma, Qiaoling
    Yang, Donglin
    Wei, Jialin
    He, Yi
    Pang, Aiming
    Feng, Sizhou
    Han, Mingzhe
    Jiang, Erlie
    HEMATOLOGY, 2023, 28 (01)
  • [49] Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
    Badar, Talha
    Atallah, Ehab
    Shallis, Rory
    Saliba, Antoine N.
    Patel, Anand
    Bewersdorf, Jan P.
    Grenet, Justin
    Stahl, Maximilian
    Duvall, Adam
    Burkart, Madelyn
    Palmisiano, Neil
    Bradshaw, Danielle
    Kubiak, Michal
    Dinner, Shira
    Goldberg, Aaron D.
    Abaza, Yasmin
    Murthy, Guru Subramanian Guru
    Kota, Vamsi
    Litzow, Mark R.
    LEUKEMIA, 2023, 37 (04) : 799 - 806
  • [50] Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease
    Zhang, Ran
    Lu, Xuan
    Wang, Huafang
    You, Yong
    Zhong, Zhaodong
    Zang, Sibin
    Zhang, Chun
    Shi, Wei
    Li, Junying
    Wu, Qiuling
    Fang, Jun
    Xia, Linghui
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (01) : 47 - 55
12345